Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model - Wikidata - wikimedia - TriplyDB

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

http://www.wikidata.org/entity/Q36841356

about

Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer PI3K and cancer: lessons, challenges and opportunities Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.Network and data integration for biomarker signature discovery via network smoothed T-statistics.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Effect of metformin on prostate cancer outcomes after radical prostatectomy Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system.Endothelial cell-derived interleukin-6 regulates tumor growth.Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling Redox regulation in cancer: a double-edged sword with therapeutic potential.Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth 3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells.eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.Molecular genetics of prostate cancer: new prospects for old challenges A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.RAS Interaction with PI3K: More Than Just Another Effector Pathway FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK.mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice.Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3-kinase-mediated Akt signaling.Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death.

P2860

Q24314709-D08ABE3F-1D1C-4903-8F46-07ED8426F69A Q24616946-DC333DA3-D624-4D14-A06B-7C1508301CF5 Q26751237-1C9C7BB5-73AA-4C88-AFFD-D63BD8A83DE0 Q26774456-42AD59A4-050B-4F49-B880-0A92D3E5E485 Q27026839-4C54AC2B-E8E6-4EED-A26C-BCCAA35DD0FF Q27341759-D0657F88-ABDB-4628-8BF2-7F2AD6D16263 Q27852136-E8ECDA2F-E655-401D-AAF7-E19766B72622 Q28076745-F7985E6A-75F4-4334-8406-D70D432D3452 Q28270006-56C617B1-C9E8-4EC9-9B43-CB6A7BC31FEF Q28479007-D19EEE36-43AE-4F95-8EB4-65E335517159 Q29618030-C4C6D3CE-5284-44F9-8EC8-FBF4F5D7B53C Q30080017-C05ED4A2-D5FD-44DF-96E3-EF343B773DC4 Q30416651-6CD942CF-75D0-4A6F-B837-63B996DA8EF2 Q30423585-5520025C-F3D4-45C8-B0BB-16AB13280317 Q30665910-7F47B699-3661-40B4-A540-8BB67EABA412 Q33439312-FAD85F4F-0BDF-4703-81C5-BD563E19F478 Q33551333-AA514244-73E9-412D-BA45-53D362E7D0CF Q33574102-24DD707B-4A81-40D4-8B93-955E0BF56729 Q33592677-D1E298FC-60D5-4350-844C-44CC2D3B580F Q33651942-21E39FA1-CA23-40F2-8D95-136D5BB709A4 Q33716894-F7514D15-DB2F-49F8-BE29-9A6FC336999A Q33770060-A992DE2E-EA3C-4963-B4C1-DC56FF5D267D Q33840360-D16D0F5E-FAD9-4A97-B7DD-CFE2ABBE2D89 Q33850663-D4D5262D-BFA6-4721-9921-6D43EA743DBC Q33925625-CE2A1E88-3BEA-4C24-BE98-8510605925CB Q33937876-1D655F18-A9AC-4CDE-AB60-5EC013FBAF00 Q33976977-431EDA3A-E8A6-42EA-8732-FA8C6E0C85BD Q34002839-9720885D-ADBE-448B-9898-00A5B5D4AB95 Q34042356-C1A282FB-AF36-4FCD-89B6-1317759E4F85 Q34069836-56F916DA-B160-4BE8-B28D-0EBA4A546500 Q34093594-1ABADC76-321A-4A06-8E03-2CCD590708B4 Q34127462-7FB2DA2A-B840-4708-9A94-537159C651A1 Q34140027-971BFEB6-A2E7-4D0F-849E-EC8611C18F1B Q34202692-5C18CB04-C87F-4EB3-87B0-B379D0AB6247 Q34269804-9B91F21A-30B8-4054-9DE7-BD2E0DBA62D5 Q34340709-635801E8-E5C3-46B9-91F7-CEE3C2F81B39 Q34429001-6EC55686-0554-4E98-87DD-AF95217FEE74 Q34566607-6B5B0F31-2405-4D05-A4CB-8D4746985ED8 Q34586319-285E27B8-5DC5-43DF-BBCE-10CAFA4B6EE8 Q34658181-D6300DC1-E1DA-4D5C-9CE5-48CF8F84E480

P2860

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

http://www.wikidata.org/entity/Q36841356

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Targeting AKT/mTOR and ERK MAP ...... r in a preclinical mouse model

@en

type

label

Targeting AKT/mTOR and ERK MAP ...... r in a preclinical mouse model

@en

prefLabel

Targeting AKT/mTOR and ERK MAP ...... r in a preclinical mouse model

@en

P1433

Q36841356-CBAD3E81-D2FF-4EA4-9A8E-43565601F015

P1476

Q36841356-5FBFD46D-45EA-49BC-80FB-237E94D31C69

P2093

Q36841356-4F5D4A75-0D98-4765-9C83-2532FE343B11

Q36841356-5A22684E-1B4F-4253-9B8B-63DB3CE45974

Q36841356-84280293-410A-40AE-B01C-126948703074

Q36841356-99D8AF17-6F37-442B-93E5-32F8E76B709D

Q36841356-B2A015F6-1F53-4A77-960A-988F60EF2629

Q36841356-B31669F7-A2BE-45DA-85AF-F6FDEBB26126

Q36841356-D245614B-5093-4F76-85A3-05155CE3630A

Q36841356-D48CB897-A7E6-494A-9944-F88E331802DB

Q36841356-DE97FBB1-2193-4C02-9545-012E9E001483

Q36841356-E6C8E155-12B0-40AE-ADC0-A9923F1A4608

P2860

Q36841356-0189ED3C-6E34-4B72-9021-C7B505509E9E

Q36841356-03915155-D881-4F41-901E-DC09C5815614

Q36841356-05FDD017-C0E6-42B7-BB90-BC6871806F9E

Q36841356-0E50DB60-B5D3-4A9E-A40F-1672A1C587BA

Q36841356-0F7567C2-FA60-4F17-B640-9BB49D96C05B

Q36841356-0FB670BB-3195-445F-96AE-EE06DF904967

Q36841356-0FFBFE67-AC7D-4A13-ADAA-223C846885D5

Q36841356-12DCDBAB-E9C3-40C9-AF53-8D76FBD51C17

Q36841356-1E7DC242-7ADA-4740-A93F-BD6BFE574EE1

Q36841356-215BCCC9-6F89-43C4-BAD3-26590B8ECC44

P304

Q36841356-DC20477C-7B4C-408D-9D05-67DBF72D9284

P31

Q36841356-35E7AA2E-F9C3-4022-B16D-8B5B8EF6A553

P356

Q36841356-19486076-4484-4B24-8CD5-1F45DD35FC91

P407

Q36841356-90D5046A-F0E9-480C-9A1A-2F1E198A0E41

P433

Q36841356-C5116188-0E9B-4097-AF05-836D2B76089E

P478

Q36841356-8A70F412-8CE9-4B7C-B1EB-3143AE2CB5FD

P50

Q36841356-9B790DF2-6280-4A6E-A59A-292F2C684FC1

P577

Q36841356-A95F3700-8F22-4975-BA4E-11B189019E74

P5875

Q36841356-92E67D94-4BEF-4C44-9646-1E734B41C4D9

P698

Q36841356-60AB7715-B28D-47FC-B157-796E5B73946E

P932

Q36841356-E5D8B39E-1E96-413F-93AA-9757E943347F

P356

P1433

Journal of Clinical Investigation

P1476

Targeting AKT/mTOR and ERK MAP ...... r in a preclinical mouse model

@en

P2093

Anna Puzio-Kuter

http://www.w3.org/2001/XMLSchema#string

Carolyn Waugh Kinkade

http://www.w3.org/2001/XMLSchema#string

Cory Abate-Shen

http://www.w3.org/2001/XMLSchema#string

Hui Gao

http://www.w3.org/2001/XMLSchema#string

Jun Yan

http://www.w3.org/2001/XMLSchema#string

Mireia Castillo-Martin

http://www.w3.org/2001/XMLSchema#string

Thomas H Foster

http://www.w3.org/2001/XMLSchema#string

William L Gerald

http://www.w3.org/2001/XMLSchema#string

Xuesong Ouyang

http://www.w3.org/2001/XMLSchema#string

Yvonne Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Upstream and downstream of mTOR

Roles for Nkx3.1 in prostate development and cancer

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

BRAF mutation predicts sensitivity to MEK inhibition

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

P304

3051-3064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI34764

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Carlos Cordon-Cardo

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23192735

http://www.w3.org/2001/XMLSchema#string

P698

18725989

http://www.w3.org/2001/XMLSchema#string

P932

2518074

http://www.w3.org/2001/XMLSchema#string